Suggestions
Oliver Venn
Statistical population genomics meets cancer biology
Oliver Venn is a highly accomplished professional in the field of bioinformatics and data science, currently serving as the Vice President of Bioinformatics and Data Science at GRAIL.12 GRAIL is a biotechnology company focused on developing blood tests for early cancer detection.1
Professional Background
Oliver Venn joined GRAIL in August 2022, taking on the role of Vice President Bioinformatics and Data Science.2 His work at GRAIL involves applying statistical population genomics to cancer biology.2 This aligns with GRAIL's mission to develop blood tests that can detect cancer early, before symptoms appear, potentially leading to higher survival rates.1
Education
Oliver Venn has an impressive educational background:
- Doctor of Philosophy (PhD) from the University of Oxford (2008-2013)2
- Double Major from Massachusetts Institute of Technology (2003-2008)2
- Exchange program at the University of Cambridge (2005-2006)2
- Engineering Leadership Professional Program at UC Berkeley College of Engineering (2019)2
Location and Connections
Oliver Venn is based in the San Francisco Bay Area.12 He has over 500 connections on LinkedIn, indicating a strong professional network in his field.2
Recent Work
In April 2023, Oliver shared information about GRAIL's new data demonstrating that their methylation assay can detect residual hematologic cancer after treatment.3 This highlights his involvement in GRAIL's cutting-edge research and development efforts in cancer detection technology.
Oliver Venn's diverse educational background and current role at GRAIL position him as a key figure in the intersection of data science, bioinformatics, and cancer research.
Highlights
Interested in the science where GRAIL identified methylated cell-free DNA as the most promising signal for multi-cancer early detection?
Now published in Cancer Cell our 2018 project that systematically evaluated alternative cell free DNA approaches for cancer detection.
From head-to-head comparison of 10 classifiers across 3 assays over 2800 participants we found that
-
Many tumors shed DNA into the circulation. That the amount varies extensively within and between types and stage. And the amount may be a critical biological property of test performance.
-
We could account for this variation to enable fairer comparison of classifier performance (we developed a new metric called clinical limit of detection which is of wide use to the field).
-
That the high-density of methylation enabled the lowest (best) clinical limit of detection at high specificity, and most accurate cancer signal origin localization.
Proud and grateful to have been a part of the large cross-functional team that delivered this work!
